Navigation Links
Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
Date:12/19/2007

patients and investors in Axentis."

Mr. Toru Gensuke Tokoro, President and CEO of aRigen Pharmaceuticals, Inc. adds: "ARB-CF0223 is based on a well-characterised drug, Tobramycin. Utilising synthetic liposomes that contain Tobramycin, a proprietary nebulizer delivers the drug directly to the endobronchial sites of infection in Cystic Fibrosis patients. This results in prolonged, high local drug concentration, which in turn achieves higher efficacy and lower doses. We are pleased that a competent partner such as Axentis Pharma will further develop this promising product."

The drug has already been tested successfully in a phase I single-dose inhalation study. No significant adverse events were observed when the liposomal formulation of Tobramycin was compared with the currently marketed formulation in 24 healthy volunteers who were treated in a crossover fashion.

About Cystic Fibrosis

Cystic Fibrosis (CF) is the most common life-threatening inherited multi-organ disease in Caucasians and is caused by a mutation in the CFTR-gene (cystic fibrosis transmembrane conductance regulator) on chromosome 7. The defective gene leads to viscous secretions and impaired mucociliary clearance. The most devastating clinical consequence of CF and cause of morbidity and mortality is lung involvement. A striking feature of lung involvement is the endobronchial colonisation with the bacterial strain Pseudomonas aeruginosa. Chronic inflammation contributes to obstructive lung disease and tissue destruction leading to bronchiectasis and respiratory failure.

About Axentis Pharma AG (http://www.axentispharma.com)

Axentis Pharma AG is a Swiss biotech company. The company owns proprietary technology used in the treatment of diseases, the etiology of which is misrouted or misfolded proteins, for example, cystic fibrosis, nephrogenic diabetes insipidus, hypercholesterolemia and others. Axentis is
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
3. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. Pharsight Achieves First License Sale for Public-Source Database
8. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
9. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
10. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... ... organized and will present a session on chemical spectroscopic imaging at JASIS 2015 ... exposition is Asia’s largest analytical and scientific instruments show which will be held ...
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , a nationwide consulting ... to announce their ranking as one of the top 5000 companies listed on the ... across the nation. , “It is truly an honor to be recognized as one ...
(Date:8/27/2015)... ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: ... three and six-month periods ended June 30, 2015. Biorem,s complete second ... www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ... , 2014 , 2015 , 2014 ... 9,398 , 4,433 Gross profit , 1,656 ...
(Date:8/27/2015)... RESEARCH TRIANGLE PARK, N.C. , Aug. 27, ... reports on the decision by FedEx, UPS and ... shipments of certain biological specimens classified as ,select ... expertise and long history of handling these sensitive ... network, knowledge of global transportation regulations, trained and ...
Breaking Biology Technology:U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... Systems, Inc., a technology leader in developing novel chip-on-catheter ... a new 510(k) clearance for its Third Eye(R) Retroscope(R) ... cancerous and pre-cancerous polyps in the colon. This ... the FDA to enhance polyp detection when used in ...
... college-aged women expert guidance in career, financial planning ... young women enter the "real world" expecting that ... it comes to their careers, finances and relationships. ... often happens -- a looming problem especially in ...
... Feb. 17 GeneGo, Inc., the leading systems ... licensed 250 manually curated pathway maps from GeneGo, ... Available at www.millipore.com/pathways , the tool links ... well as relevant bioinformatics content to related biological ...
Cached Biology Technology:Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 2Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 3Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 4Helping Young Women Succeed in Today's Unpredictable World 2Helping Young Women Succeed in Today's Unpredictable World 3Helping Young Women Succeed in Today's Unpredictable World 4Millipore Launches an Interactive Biological Pathway Tool Using GeneGo's Manually Curated Pathway Maps 2Millipore Launches an Interactive Biological Pathway Tool Using GeneGo's Manually Curated Pathway Maps 3
(Date:8/4/2015)... 2015  AMRI (NASDAQ: AMRI ) today reported financial and ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 % ... a $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial ...
(Date:7/31/2015)... juli 2015 Den 10. internationale konference om ... den 22. - 25. oktober i Shenzhen ... 10-års fødselsdag i år. Siden starten i 2006 er ... på ,omik,-feltet, og er en af de mest dynamiske, ... fokuserer på nylige gennembrud og fremskridt inden for ,omik,-forskning, ...
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... National Institutes of Health has awarded 23 grants for ... five years. The projects will focus on determining the ... medicine. The awards are part of the ... 2000 with the main goal of developing highly efficient, ...
... the millions of Americans with high blood pressure, more help ... published in the October 2010 print issue of The ... called P450, metabolizes arachidonic acid in our blood vessel walls ... (EET)which in mice, turns off genes responsible for vascular inflammation ...
... Arizona State University has been awarded a $7.7 million ... of General Medical Sciences, part of the National Institutes of ... a key role in protection against infectious diseases. As ... Chemistry and Biochemistry in the College of Liberal Arts and ...
Cached Biology News:NIH grants will advance studies of the form and function of proteins 2NIH grants will advance studies of the form and function of proteins 3Scientists discover a new way our bodies control blood pressure: the P450-EET system 2NIH funds center at Arizona State to battle infectious diseases 2NIH funds center at Arizona State to battle infectious diseases 3
... thermostable DNA polymerase obtained by high level ... in E. coli, Concentration: 5U/ul, Applications: Standard ... Scientific, the world leader in serving science. ... the world healthier, cleaner and safer by ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... is a thermostable DNA polymerase derived ... at temperatures above 70°C, it was ... PCR and remains the predominant enzyme ... an intrinsic 5'?3' structure-dependent exonuclease activity, ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Biology Products: